A Clinical Study Evaluating the Safety, Tolerability and Efficacy of the Neoantigen-based Personalized mRNA Therapeutic Technology iNeo-Vac-R01 in Combination With a PD-1 Immune Checkpoint Inhibitor for Adjuvant Therapy After Radical Resection of Liver Cancer
Latest Information Update: 02 Apr 2026
At a glance
- Drugs INeo Vac R01 (Primary)
- Indications Liver cancer
- Focus Adverse reactions
Most Recent Events
- 02 Apr 2026 New trial record